We just published a review article at #JIPO exploring challenges and future perspectives targeting #TME 🧬 great collaboration !

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm An excellent review👇 nature.com/articles/s4157…

Interesting trial!

We need to talk with our patients about financial toxicity and offer them available resources to help with financial burden.

We were just notified all NIH nickCTEP_ClinRes @NCI meetings are now CANCELLED. Investigators PLS continue your hard work and dedication to make a difference. #Cancer is indifferent to politics and impacts everyone. @asco #ASCOGI25 #CancerResearch science.org/content/articl…

Interesting findings but concerning …

DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! OncoAlert OncoDaily Daiichi Sankyo US AstraZeneca daiichisankyo.com/files/news/pre…

Just published in Journal of Clinical Oncology the updated ASCO guidelines on fertility preservation in people with #cancer: a must read for all colleagues involved in cancer care to increase awareness on #oncofertility issues OncoAlert Ann Partridge MD, MPH Oncofertility Link: ascopubs.org/doi/10.1200/JC…

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC

💊 Can DFS be used as a surrogate for OS in early-stage pancreatic cancer trials? 📈 In a meta-analysis of 29 RCTs (n=6777), DFS strongly correlated with OS (R=0.70 adjuvant | R=0.90 neoadjuvant). 📍 DFS may be a reliable surrogate endpoint for OS. bmjoncology.bmj.com/content/bmjonc…

📄 Our publication in JCO Global Oncology: ascopubs.org/doi/10.1200/GO… We analyzed global trends in early-onset pancreatic cancer: 🔍 Key insights (1990–2021): ✅ Incidence ↑ 63% ✅ Mortality ↑ 57%, especially in middle SDI regions ⚠️ Leading risk factors: Smoking and Obesity

Excited to share that I’ve graduated from the VA Quality Scholars Advanced Fellowship! Grateful to the 2 years VAQS program and University of Toronto for this incredible opportunity. Looking forward to advancing Quality Improvement and Patient Safety in cancer care! #VAQS #UofT

Presented at #ASCO25: In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade. Full DESTINY-Gastric04 trial:

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

#MATTERHORN trial was one of the best studies at #ASCO2025 - addition of durvalumab to SOC preoperatively FLOT was positive for EFS in gastric cancer pts. That study brings #hope and possible increased chances of #cure. Looking forward to seeing the survival data in the future

This is an alert for physicians and patients!

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25%

This will support even more our HPB tumor boards discussions !